TOKIWA Bio to supply clinical-grade SRV vectors for making iPS cells from 2027

TOKIWA Bio plans to supply its Stealth RNA Vector (SRV) for making iPS cells in clinical grade from the first quarter of 2027, Nikkei Biotech reported on October 14, 2026. The viral testing needed for clinical supply will be outsourced to TFBS Bioscience, a Taiwanese provider of biosafety testing. The two companies signed a strategic alliance in cell therapy and regenerative medicine on October 8, at the BioJapan 2026 show in Yokohama. Neither disclosed the contract value or other terms.

iPS cells are made by introducing several reprogramming factors into blood or skin cells. The factors can be delivered by Sendai virus vectors, mRNA or episomal vectors, among other tools. Labs have chosen among them on reprogramming efficiency and on whether anything of the factors stays in the cells afterward.

SRV has a negative-sense single-stranded RNA genome and keeps expressing its genes stably for a long time in the cytoplasm. According to TOKIWA Bio, one vector can carry 10 or more genes at once and can be cleared from the cells quickly once its job is done. The company also says the vector does not enter the chromosomes. That property suits cell lines meant for the clinic, where developers want to limit the risk of insertional mutagenesis. On October 7 TOKIWA Bio separately announced a new product for making iPS cells, SRV iPSC-5.

A raw material that cannot be swapped later

Biological raw materials used for clinical products must come with tests showing that no other virus got in during their manufacture. A reprogramming vector is the first raw material an iPS cell line ever touches. If a line made with a research-grade vector goes to the clinic, its developer has to trace that vector's origin and test records back and justify them. If that is not possible, the line has to be derived again. A new line also means repeating the karyotype and genomic stability checks before it can be differentiated toward a product.

In an October 6 release, the Taiwanese delegation to BioJapan described the alliance as combining TFBS's biosafety testing with TOKIWA Bio's SRV technology and its banks of human primary cells, to support the quality and safety of new therapies. A vector supplier that has already settled where its testing is done gives users a cleaner basis for accepting the material.

With a supply date for a clinical-grade reprogramming vector on the table, developers can plan research-stage iPS cell lines with clinical use in mind from the first step.